Literature DB >> 2036659

Role of tumour necrosis factor in the tumour-necrotizing activity of agents with diverging toxicity.

P A van de Wiel1, A van der Pijl, N Bloksma.   

Abstract

We investigated the ability of various tumour-necrotizing agents with diverging toxicity to induce tumour necrosis factor (TNF) and cytostatic activity in Propionibacterium-acnes-primed Swiss and tumour-bearing BALB/c mice, and the capacity of anti-TNF antibodies to inhibit induction of tumour necrosis by the agents. Lipid A and especially its combination with muramyl dipeptide induced high TNF levels in Swiss mice, as measured in the serum. Lower levels were induced by detoxified lipid A and the nontoxic dsRNA, polyadenylic.polyuridylic acid, either alone or combined with muramyl dipeptide. The toxic agents also appeared the strongest inducers of mediators with cytostatic activity against cultured endothelial cells and MethA tumour cells. Anti-TNF antibodies partially reduced the cytostatic activity of the sera against MethA cells. Tumour-bearing BALB/c mice produced only low levels of TNF and cytostatic factors in response to all agents. Recombinant mouse TNF hardly reduced the DNA synthesis of MethA cells, unless normal mouse serum was added. Serum from P.-acnes-treated Swiss mice and tumour-bearing BALB/c mice, that were inhibitory on their own, failed to potentiate the action of TNF. Serum from Swiss mice treated with toxic, but not detoxified, lipid A caused extensive tumour necrosis upon injection into MethA-bearing BALB/c mice. This activity was completely abolished by pre-incubation of the serum with anti-TNF. The tumour-necrotizing activity of the agents could be partially reduced by prior injection of these antibodies. Results show that the capacity of the agents to induce TNF and cytostatic activity is not related to their antitumour potential. Although TNF is likely to be a crucial mediator of the tumour-necrotizing action of the toxic as well as the nontoxic agents, it is probably not the sole mediator. Data also indicate that induction of tumour necrosis does not require induction of high and, thus toxic, TNF levels in the serum.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2036659     DOI: 10.1007/bf01742539

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  20 in total

Review 1.  The role of cachectin/TNF in endotoxic shock and cachexia.

Authors:  A Cerami; B Beutler
Journal:  Immunol Today       Date:  1988-01

2.  Proposal of standardized methods and reference for assaying recombinant human tumor necrosis factor.

Authors:  S Yamazaki; E Onishi; K Enami; K Natori; M Kohase; H Sakamoto; M Tanouchi; H Hayashi
Journal:  Jpn J Med Sci Biol       Date:  1986-06

3.  A phase I clinical trial of recombinant human tumor necrosis factor.

Authors:  E T Creagan; J S Kovach; C G Moertel; S Frytak; L K Kvols
Journal:  Cancer       Date:  1988-12-15       Impact factor: 6.860

4.  Endotoxin-induced antitumor activity in the mouse is highly potentiated by muramyl dipeptide.

Authors:  N Bloksma; F M Hofhuis; J M Willers
Journal:  Cancer Lett       Date:  1984-06       Impact factor: 8.679

5.  Muramyl dipeptide is a powerful potentiator of the antitumor action of various tumor-necrotizing agents.

Authors:  N Bloksma; F M Hofhuis; J M Willers
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

6.  Macroscopic and microscopic early effects of tumour necrosis factor on murine Meth A sarcoma, and relation to curative activity.

Authors:  P A Van de Wiel; N Bloksma; C F Kuper; F M Hofhuis; J M Willers
Journal:  J Pathol       Date:  1989-01       Impact factor: 7.996

7.  Antitumour activity of endotoxin, concanavalin A and poly I: C and their ability to elicit tumour necrosis factor, cytostatic factors, and interferon in vivo.

Authors:  N Bloksma; C F Kuper; F M Hofhuis; B Benaissa-Trouw; J M Willers
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

8.  Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity.

Authors:  M A Palladino; M R Shalaby; S M Kramer; B L Ferraiolo; R A Baughman; A B Deleo; D Crase; B Marafino; B B Aggarwal; I S Figari
Journal:  J Immunol       Date:  1987-06-01       Impact factor: 5.422

9.  Modulation of endothelial cell hemostatic properties by tumor necrosis factor.

Authors:  P P Nawroth; D M Stern
Journal:  J Exp Med       Date:  1986-03-01       Impact factor: 14.307

10.  Differences in tumour necrosis factor productive ability among rodents.

Authors:  K Haranaka; N Satomi; A Sakurai
Journal:  Br J Cancer       Date:  1984-10       Impact factor: 7.640

View more
  1 in total

1.  Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors.

Authors:  Nicolas Isambert; Pierre Fumoleau; Catherine Paul; Christophe Ferrand; Sylvie Zanetta; Jacques Bauer; Kevin Ragot; Gérard Lizard; Jean-François Jeannin; Marc Bardou
Journal:  BMC Cancer       Date:  2013-04-02       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.